Uwell Biopharma, Inc. (TPEX:7902)

Uwell Biopharma Statistics

Total Valuation

Uwell Biopharma has a market cap or net worth of TWD 8.20 billion. The enterprise value is 7.88 billion.

Market Cap	8.20B
Enterprise Value	7.88B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Uwell Biopharma has 200.00 million shares outstanding. The number of shares has increased by 31.83% in one year.

Current Share Class	200.00M
Shares Outstanding	200.00M
Shares Change (YoY)	+31.83%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	22.71%
Owned by Institutions (%)	n/a
Float	107.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	234,285.71
PB Ratio	24.52
P/TBV Ratio	24.52
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-119.10
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-145.05

Financial Position

The company has a current ratio of 24.61, with a Debt / Equity ratio of 0.01.

Current Ratio	24.61
Quick Ratio	24.57
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-449.91

Financial Efficiency

Return on equity (ROE) is -33.18% and return on invested capital (ROIC) is -20.93%.

Return on Equity (ROE)	-33.18%
Return on Assets (ROA)	-20.10%
Return on Invested Capital (ROIC)	-20.93%
Return on Capital Employed (ROCE)	-20.35%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	42.64
200-Day Moving Average	n/a
Relative Strength Index (RSI)	43.92
Average Volume (20 Days)	382,103

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Uwell Biopharma had revenue of TWD 35,000 and -66.20 million in losses. Loss per share was -0.43.

Revenue	35,000
Gross Profit	28,000
Operating Income	-68.39M
Pretax Income	-66.20M
Net Income	-66.20M
EBITDA	-60.33M
EBIT	-68.39M
Loss Per Share	-0.43

Balance Sheet

The company has 320.24 million in cash and 4.26 million in debt, with a net cash position of 315.98 million or 1.58 per share.

Cash & Cash Equivalents	320.24M
Total Debt	4.26M
Net Cash	315.98M
Net Cash Per Share	1.58
Equity (Book Value)	334.38M
Book Value Per Share	1.75
Working Capital	308.21M

Cash Flow

In the last 12 months, operating cash flow was -52.31 million and capital expenditures -2.05 million, giving a free cash flow of -54.36 million.

Operating Cash Flow	-52.31M
Capital Expenditures	-2.05M
Depreciation & Amortization	8.06M
Net Borrowing	-5.33M
Free Cash Flow	-54.36M
FCF Per Share	-0.27

Margins

Gross Margin	80.00%
Operating Margin	-195,391.43%
Pretax Margin	-189,137.14%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Uwell Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.83%
Shareholder Yield	-31.83%
Earnings Yield	-0.81%
FCF Yield	-0.66%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3